SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 7/16/20

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Infrainguinal revascularized PAD (2)	Phase III	
		Pediatric VTE (2)	Phase III	
	INVOKANA® (canagliflozin)	Treatment of Diabetic Kidney Disease in adults with T2DM (2)	Approved 9/19	Approved 6/20
	aprocitentan	Difficult to treat hypertension (2)	Phase III	Phase III
Immunology	TREMFYA® (guselkumab)	Psoriatic arthritis	Approved 7/20	Filed 10/19
		Crohn's Disease	Phase IIB/III	Phase IIB/III
		Pediatric Psoriasis	Phase III	Phase III
		UC Monotherapy	Phase IIB/III	Phase IIB/III
	SIMPONI®	Pediatric Ulcerative Colitis	Phase III	Phase III
	SIMPONI ARIA®	Polyarticular Juvenile Idiopathic Arthritis (pJIA)	Filed 3/20	
		Juvenile Psoriatic Arthritis (jPsA)	Filed 3/20	
	STELARA® (ustekinumab)	Pediatric Psoriasis (6-11 year-olds)	Filed 9/19	Approved 1/20
Infectious Diseases and Vaccines	Rilpivirine Long Acting nanosuspension for injection	HIV Infection	Complete Response 12/19	Filed 7/19
	pimodivir (JNJ-3872)	Influenza A (2)	Phase III	Phase III
	VAC52150	Monovalent Ebola Virus Vaccine	Phase III	Approved 7/20
	VAC89220	HIV Px Vaccine	Phase III	Phase III
Neuroscience	SPRAVATO™ (esketamine)	Major Depressive Disorder with Active Suicidal Ideation and Intent	Filed 10/19	Filed 1/20
	ponesimod	Monotherapy for multiple sclerosis	Filed 3/20	Filed 3/20
	paliperidone palmitate 6 month long-acting injectable	Treatment of Schizophrenia	Phase III	Phase III
Oncology	DARZALEX®	Relapsed Refractory MM 1+ prior lines w/PomDex (2)	Phase III	Phase III
		Relapsed Refractory multiple myeloma w/carfilzomib/dex (Amgen sponsored) (2)	Filed 2/20	
		Amyloidosis (AMY 3001) (2)	Phase III	Phase III
		Smoldering multiple myeloma (SMM3001) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant ineligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3019, CEPHEUS) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant eligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3014, PERSEUS) (2)	Phase III	Phase III
		Subcutaneous Formulation in patients with relapsed or refractory multiple myeloma (MMY3012, COLUMBA) (2)	Approved 5/20	Approved 6/20
	IMBRUVICA® (ibrutinib)	Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2)	Phase III	Phase III
		Relapsed/refractory patients with Indolant Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2)	Phase III	Phase III
		Frontline Chronic Lymphocytic Leukemia in combination with Rituximab (Young and Fit) (ECOG 1912) (2)	Approved 4/20	Filed 1/20
		Frontline Chronic Lymphocytic Leukemia in combination with venetoclax (fixed duration) (GLOW) (2)	Phase III	Phase III
		Relapsed/refractory patients with Mantle Cell Lymphoma in combination with venetoclax (PCYC-1143) (2)	Phase III	Phase III
	ERLEADA® (apalutamide)	Localized prostate cancer	Phase III	Phase III
		High risk prostate cancer (PROTEUS)	Phase III	Phase III
	apalutamide/ abiraterone acetate	Prostate Cancer metastatic castration resistant chemotherapy naïve	Phase III	Phase III
	BALVERSA™ (erdafitinib)	Urothelial cancer (2)	Approved 4/19	Phase III
		Tumor Agnostic	Phase IIB	Phase IIB
	niraparib / abiraterone acetate	L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone	Phase III	Phase III
	Ciltacabtagene Autoleucel (BCMA CAR-T)	Relapsed refractory multiple myeloma (2)	Phase II	Phase II
	Amivantamab (EGFR/cMET)	Non Small Cell Lung Cancer	Phase II	Phase II
Pulmonary Hypertension	OPSUMIT®	Fontan-palliated in adolescent (>12 years old) and adult patients	Phase III	Phase III
		Pediatric pulmonary arterial hypertension	Phase III	Phase III
		Chronic thromboembolic pulmonary hypertension	Complete Response 1/19	Submission Withdrawn 11/19
	UPTRAVI®	Pulmonary arterial hypertension IV	Phase III	
		Chronic thromboembolic pulmonary hypertension	Phase III	Phase III
		Pediatric pulmonary arterial hypertension	Phase III	
	Macitentan w/tadalafil FDC	Pulmonary arterial hypertension	Phase III	Phase III

*** This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.**

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; Long acting HIV injectable treatment regimen of rilpivirine and cabotegravir developed in collaboration with ViiV Healthcare Ltd; aprocitentan developed in collaboration with Idorsia; XARELTO co-developed with Bayer HealthCare; paliperidone palmitate includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech; Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S.

Janssen Pharmaceutical Companies of Johnson & Johnson
Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
Selective Highlights as of July 16, 2020

NMEs APPROVED 2019 & 2020

Oncology

ERLEADA® (apalutamide) (EU)
Non-metastatic prostate cancer

BALVERSA™ (erdafitinib) (US)
Urothelial cancer

Neuroscience

SPRAVATO™ (Esketamine)
Treatment resistant depression

Infectious Diseases & Vaccines

Monovalent Ebola Vaccine (EU)
Ebola virus Disease

NMEs IN REGISTRATION

Neuroscience

Ponesimod
Monotherapy for multiple sclerosis

NME PLANNED FILINGS 2020-2023*

Oncology

Niraparib
Metastatic castration-resistant prostate cancer (mCRPC)

Ciltacabtagene Autoleucel (BCMA CAR-T)
Multiple Myeloma

BALVERSA™ (erdafitinib) (EU)
Urothelial cancer

Cusatuzumab
Acute myeloid leukemia

Amivantamab (EGFR/cMET)
Non Small Cell Lung Cancer

JNJ-7957 (BCMA/CD3), JNJ-7564 (GPRC5D/CD3)
Multiple myeloma

Immunology

JNJ-4500 Anti-NKG2D
Crohn's disease

Neuroscience

Seltorexant
Adjunctive treatment for major depressive disorder with insomnia symptoms

Infectious Diseases & Vaccines

Pimodivir
Influenza A

RSV Sr vaccine
RSV vaccine

Cardiovascular & Metabolism

RPGR AAV Gene Therapy
X-linked retinitis pigmentosa

Aprocitentan
Difficult to treat hypertension

*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; BCMA CAR-T licensed from Legend Biotech; Cusatuzumab licensed from Argenx; Lazertinib licensed from Yuhan Corporation; JNJ-4500 Anti-NKG2D licensed from Novo Nordisk; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx; Seltorexant being developed in collaboration with Minerva Neurosciences; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (JNJ-6372, JNJ-7957, JNJ-7564); Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S.